{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:36:24Z","timestamp":1794533784954,"version":"4.9.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:sec><jats:title>Summary:<\/jats:title><jats:p>In this issue of Blood Cancer Discovery, Neri, Barwick, and colleagues and Welsh, Barwick, and colleagues performed RNA sequencing, chromatin immunoprecipitation sequencing, assay for transposase-accessible chromatin using sequencing, and genetic studies to characterize the underlying mechanisms of immunomodulatory drug (IMiD) resistance in multiple myeloma. They demonstrated that IMiD resistance is driven by sustained expression of MYC and IRF4 via transcriptional plasticity that involves induction of ETV4 and BATF proteins, the binding of these proteins to their super-enhancers, and the recruitment of BRD4 and p300. Finally, these studies suggest IMiD and p300 inhibitor combination as a promising therapeutic strategy in multiple myeloma.<\/jats:p><jats:p>See related article by Neri, Barwick, et al., p. 56 (9).<\/jats:p><jats:p>See related article by Welsh, Barwick, et al., p. 34 (10).<\/jats:p><\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0223","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:02:51Z","timestamp":1702400571000},"page":"5-7","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-1635","authenticated-orcid":false,"given":"Seongseok","family":"Yun","sequence":"first","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9065","authenticated-orcid":false,"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[{"name":"2Department of Tumor Microenvironment & Meta\u00adstasis, Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"2024010808143312600_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2024010808143312600_bib2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2024010808143312600_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"2024010808143312600_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2024010808143312600_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14289","article-title":"Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice","volume":"521","author":"Adam","year":"2015","journal-title":"Nature"},{"key":"2024010808143312600_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"2024010808143312600_bib7","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"key":"2024010808143312600_bib8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"key":"2024010808143312600_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2024010808143312600_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0223\/3390821\/bcd-23-0223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/5\/3397533\/5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/5\/3397533\/5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:54:29Z","timestamp":1730840069000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/1\/5\/732329\/Transcriptional-Plasticity-Drives-IMiD-and-p300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,12]]},"published-print":{"date-parts":[[2024,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0223","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}